Novartis: Switching to Gilenya from IFN improves LT outcomes

BUY, Fair Value CHF77 (+15%)

News published on June Monday 10, 2013
Share on

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities